B of A Securities Maintains Buy on Ultragenyx Pharmaceutical, Lowers Price Target to $58

Benzinga · 3d ago
B of A Securities analyst Tazeen Ahmad maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and lowers the price target from $72 to $58.